CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt
https://www.fiercebiotech.com/biotech/cytomx-slashes-headcount-40-after-breast-cancer-setback-later-stage-development-bearing
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.